Global Research Trends in Immunotherapy for Non-small Cell Lung Cancer Patients with KRAS Mutations: a Bibliometric Analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 May 31

PMID 38817907

Authors

Hanyu Shen

Chunxiao Li

Affiliations

Soon will be listed here.

Abstract

Background: Immunotherapy, frequently combined with conventional chemotherapy, is crucial for treating NSCLC. Kirsten rat sarcoma virus (KRAS) is a poor prognostic factor in patients with NSCLC, particularly lung adenocarcinoma, where binding of conventional inhibitors to mutated KRAS proteins is challenging. Field profiles, research hotspots, and prospects for immunotherapy for patients with NSCLC-carrying KRAS mutations were uncovered in this study.

Methods: Microsoft Excel 2019, Bibliometrix, VOSviewer software, and Citespace were utilized to conduct a comprehensive scientometric analysis and understand a specific research field's knowledge base and frontiers aided by bibliometrics.

Results: Between 2014 and 2023, 398 eligible documents in the English language were acquired using the WoSCC database, of which 113 and 285 were reviews and articles, respectively. The growth rate per year was 34.25 %. The most cited articles were from the United States, and China published the highest number of articles. Cancers was the journal, with increased publications in recent years. The keywords with the strongest citation bursts were analyzed using Citespace. "Immune checkpoint inhibitors," "co-occurring genomic alterations," and "KRAS" are among the research hotspots in this field.

Conclusion: Using bibliometric and visual analyses, we examined immunotherapy for patients with KRAS-mutant NSCLC over the previous decade. The whole analysis showed a steady, quick increase in yearly publications in this area. Our findings will provide a roadmap for future research on the mechanisms of immunotherapy and immune checkpoint inhibitor action in treating KRAS-mutant NSCLC.

References

Jeanson A, Tomasini P, Souquet-Bressand M, Brandone N, Boucekine M, Grangeon M . Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol. 2019; 14(6):1095-1101. DOI: 10.1016/j.jtho.2019.01.011. View

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

Negrao M, Araujo H, Lamberti G, Cooper A, Akhave N, Zhou T . Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023; 13(7):1556-1571. PMC: 11024958. DOI: 10.1158/2159-8290.CD-22-1420. View

Liu C, Zheng S, Jin R, Wang X, Wang F, Zang R . The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett. 2019; 470:95-105. DOI: 10.1016/j.canlet.2019.10.027. View

Hong D, Fakih M, Strickler J, Desai J, Durm G, Shapiro G . KRAS Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020; 383(13):1207-1217. PMC: 7571518. DOI: 10.1056/NEJMoa1917239. View

Li Y, Lv M, Liu J, Ma J, Liang M, Zheng N . The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis. Cancer Manag Res. 2021; 13:1383-1393. PMC: 7887431. DOI: 10.2147/CMAR.S270099. View

Mahadevan K, McAndrews K, LeBleu V, Yang S, Lyu H, Li B . KRAS inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8 T cells. Cancer Cell. 2023; 41(9):1606-1620.e8. PMC: 10785700. DOI: 10.1016/j.ccell.2023.07.002. View

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Batrash F, Kutmah M, Zhang J . The current landscape of using direct inhibitors to target KRAS-mutated NSCLC. Exp Hematol Oncol. 2023; 12(1):93. PMC: 10625227. DOI: 10.1186/s40164-023-00453-8. View

10.

Duma N, Santana-Davila R, Molina J . Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc. 2019; 94(8):1623-1640. DOI: 10.1016/j.mayocp.2019.01.013. View

11.

Ashok Kumar P, Graziano S, Danziger N, Pavlick D, Severson E, Ramkissoon S . Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency. Cancer Med. 2022; 12(2):1157-1166. PMC: 9883541. DOI: 10.1002/cam4.4971. View

12.

Cekani E, Epistolio S, Dazio G, Cefali M, Wannesson L, Frattini M . Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers. Cancers (Basel). 2022; 14(17). PMC: 9454753. DOI: 10.3390/cancers14174103. View

13.

Liu Y, Xu Y, Cheng X, Lin Y, Jiang S, Yu H . Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. Front Immunol. 2022; 13:862084. PMC: 9044908. DOI: 10.3389/fimmu.2022.862084. View

14.

Barsouk A, Friedes C, Iocolano M, Doucette A, Cohen R, Robinson K . Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation. Clin Lung Cancer. 2024; 25(3):e161-e171. DOI: 10.1016/j.cllc.2023.12.009. View

15.

Skoulidis F, Goldberg M, Greenawalt D, Hellmann M, Awad M, Gainor J . Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. Cancer Discov. 2018; 8(7):822-835. PMC: 6030433. DOI: 10.1158/2159-8290.CD-18-0099. View

16.

Sun L, Hsu M, Cohen R, Langer C, Mamtani R, Aggarwal C . Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. JAMA Oncol. 2021; 7(6):937-939. PMC: 8050787. DOI: 10.1001/jamaoncol.2021.0546. View

17.

Koyama S, Akbay E, Li Y, Aref A, Skoulidis F, Herter-Sprie G . STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 2016; 76(5):999-1008. PMC: 4775354. DOI: 10.1158/0008-5472.CAN-15-1439. View

18.

Spagnuolo A, Maione P, Gridelli C . The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative review. Transl Lung Cancer Res. 2022; 11(6):1199-1216. PMC: 9271439. DOI: 10.21037/tlcr-21-948. View

19.

Skoulidis F, Li B, Dy G, Price T, Falchook G, Wolf J . Sotorasib for Lung Cancers with p.G12C Mutation. N Engl J Med. 2021; 384(25):2371-2381. PMC: 9116274. DOI: 10.1056/NEJMoa2103695. View

20.

Cao H, Ma Z, Huang Q, Han H, Li Y, Zhang Y . Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma. Eur J Cancer. 2024; 202:113985. DOI: 10.1016/j.ejca.2024.113985. View